Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 9899
Date Received: 24/03/2025
Summary:
1. The total number of critical care beds (ICU) available within your health board area, please break this down by the number of beds at each hospital 2. The total number of critical care beds (ICU) available within your health board area as of January 1st of each of the past 5 years (2021-2025). Please break this down by number of beds available each year 3. Monthly or weekly data on critical care bed (ICU) availability for patients for each month in the past 12 months (March 1st 2024 - March 1st 2025) 4. Monthly or weekly data on critical care bed (ICU) occupancy for each month in the past 12 months (March 1st 2024 - March 1st 2025) 5. The daily average for the number of critical care (ICU) beds available for patients each month in the past 12 months (March 1st 2024 - March 1st 2025) 6. The number of instances of critical care (ICU) beds being unavailable due to staffing shortages for each year in the past 5 years (2021-2025)
Date of Response: 21/04/2025
View Response: 9899.pdf
Freedom of Information Request Reference: 9898
Date Received: 24/03/2025
Summary:
I am writing to inquire about the medical services your hospital offers for patients suffering from severe lung disease.
Date of Response: 14/04/2025
View Response: 9898.pdf
Freedom of Information Request Reference: 9897
Date Received: 24/03/2025
Summary:
I would like to determine whether Animal Assisted Therapies are offered within the trust/ service as treatments/interventions to NHS patients. I would like to determine how much is spent on these treatments/interventions. I would like to determine who offers these treatments, is it NHS clinicians, or other outside organisations and or volunteers.
Date of Response: 17/04/2025
View Response: 9897.pdf
Freedom of Information Request Reference: 9896
Date Received: 13/03/2025
Summary:
Request in relation to job application.
Date of Response: 11/04/2025
View Response: 9896.pdf
Freedom of Information Request Reference: 9895
Date Received: 21/03/2025
Summary:
Has your health board piloted self-sampling as a means of identifying cervical cancer in women?
Date of Response: 18/04/2025
View Response: 9895.pdf
Freedom of Information Request Reference: 9894
Date Received: 21/03/2025
Summary:
Would you please supply a copy of your current chaperone policy, if this policy is being updated or reviewed, please indicate this in your response?
Date of Response: 11/04/2025
View Response: 9894.pdf
Freedom of Information Request Reference: 9892
Date Received: 21/03/2025
Summary:
I am looking to find out information on the number of diagnostic radiographers employed by NHS Lothian at the start of 2025. This includes diagnostic radiographers working in all types of imaging modalities (e.g. x-ray, CT, MRI, ultrasound/sonography, mammography, nuclear medicine). I am specifically looking for data for February 2025 or the most up-to-date figures if data from February 2025 is not yet available. Questions How many diagnostic radiographers were employed by NHS Lothian in February 2025? How many diagnostic radiographers employed by NHS Lothian have been qualified for less than 1 year?
Date of Response: 17/04/2025
View Response: 9892.pdf
Freedom of Information Request Reference: 9891
Date Received: 21/03/2025
Summary:
How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one? How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Olaparib + Bevacizumab Niraparib Rucaparib Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with: Olaparib Olaparib + Bevacizumab Niraparib Other treatments
Date of Response: 17/04/2025
View Response: 9891.pdf
Freedom of Information Request Reference: 9890
Date Received: 18/03/2025
Summary:
I am looking for information regarding patients attending A&E for mental health reasons. As such, can I request the following for the calendar years 2019, 2020, 2021, 2022, 2023, 2024, 2025 (most recent) The number of patients, with an age breakdown, who have attended A&E due to mental health reasons? The number of patients, with an age breakdown, who have attended A&E due to self-harm or attempted suicide? The number of mental health patients, with an age breakdown, who are readmitted through A&E following a recent hospital discharge (within 7 days)?
Date of Response: 15/04/2025
View Response: 9890.pdf
Freedom of Information Request Reference: 9889
Date Received: 19/03/2025
Summary:
I would like to request an update on the Early Access Program EAP for Givinostat. What is the current status of the EAP for Givinostat (Duvyzat) treatment for DMD?
Date of Response: 16/04/2025
View Response: 9889.pdf
Freedom of Information Request Reference: 9887
Date Received: 19/03/2025
Summary:
Could you also please provide information in regards to NHS Lothian staff? please include requested data from the Royal Edinburgh Hospital, regarding staff who have been sacked for not wearing a face mask from date 01/01/2021 to present date. Please also include data for staff who have been sacked for not agreeing to the COV19 vaccine.
Date of Response: 16/04/2025
View Response: 9887.pdf
Freedom of Information Request Reference: 9885
Date Received: 19/03/2025
Summary:
1. Can you please provide the number of patients on the Unlicensed Sirolimus Ointment for the treatment of facial angiofibroma associated with tuberous sclerosis. 2. Out of the patients on the Unlicensed Sirolimus Ointment for the treatment of facial angiofibroma associated with tuberous sclerosis please could you let me know how many are on a dose of 0.1%, 0.2% and 0.5% .With a timeframe for any usage in 2024to date.
Date of Response: 16/04/2025
View Response: 9885.pdf
Freedom of Information Request Reference: 9884
Date Received: 19/03/2025
Summary:
Please provide the number of total cases for each illness reported within your trust between 2014 and 2024, broken down by year. The main questions and a) are a priority, but if it does not exceed the cost please also provide answers to b) (broken down by adults and children if possible). 1. How many cases of rickets were reported between 2014 and 2024 (please break down by year). a. How many of these cases were children (under 18)? b. Please provide the number of death certificates where rickets was listed as an underlying cause or a contributory factor in the last 10 years. 2. How many cases of tuberculosis were reported between 2014 and 2024 (please break down by year). a. How many of these cases were children (under 18)? b. Please provide the number of death certificates where tuberculosis was listed as an underlying cause or a contributory factor in the last 10 years. 3. How many cases of scurvy were reported between 2014 and 2024 (please break down by year). a. How many of these cases were children (under 18)? b. Please provide the number of death certificates where scurvy was listed as an underlying cause or a contributory factor in the last 10 years. 4. How many cases of malnutrition were reported between 2014 and 2024 (please break down by year). a. How many of these cases were children (under 18)? b. Please provide the number of death certificates where malnutrition was listed as an underlying cause or a contributory factor in the last 10 years. 5. How many cases of scarlet fever were reported between 2014 and 2024 (please break down by year). a. How many of these cases were children (under 18)? b. Please provide the number of death certificates where scarlet fever was listed as an underlying cause or a contributory factor in the last 10 years. 6. How many cases of syphilis were reported between 2014 and 2024 (please break down by year). a. How many of these cases were children (under 18)? b. Please provide the number of death certificates where syphilis was listed as an underlying cause or a contributory factor in the last 10 years. 7. How many cases of scabies were reported between 2014 and 2024 (please break down by year). a. How many of these cases were children (under 18)? b. Please provide the number of death certificates where scabies was listed as an underlying cause or a contributory factor in the last 10 years. 8. How many cases of whooping cough were reported between 2014 and 2024 (please break down by year). a. How many of these cases were children (under 18)? b. Please provide the number of death certificates where whooping cough was listed as an underlying cause or a contributory factor in the last 10 years 9. How many cases of measles were reported between 2014 and 2024 (please break down by year). c. How many of these cases were children (under 18)? c. Please provide the number of death certificates where measles was listed as an underlying cause or a contributory factor in the last 10 years
Date of Response: 16/04/2025
View Response: 9884.pdf
Freedom of Information Request Reference: 9883
Date Received: 19/03/2025
Summary:
The number of GPs in NHS Lothian who do not offer diabetes services as part of their services. The number of GPs who have opted out of diabetes services in the last 6 months.
Date of Response: 16/04/2025
View Response: 9883.pdf
Freedom of Information Request Reference: 9882
Date Received: 19/03/2025
Summary:
1) We have the following formularies listed as used by the organisation: East Region Formulary Please confirm if this is correct and if not, please provide any relevant online links or copies of formularies. 2) We understand the following committees maintain the formularies in question 1: East Region Formulary Committee NHS Borders, NHS Fife and NHS Lothian’s Area Drug and Therapeutics Committees (ADTCs) Please confirm if this is correct. If not correct, please list the relevant committees with the corresponding formulary. 3) Does the organisation have representation on the committees listed in question 2? 4) Are any of the above formularies listed in question 1 dominant when making prescribing decisions or does this depend on therapy area? Please say which is the dominant formulary of the organisation. 5) If you use a PDF formulary, have you considered moving it to an online platform like Netformulary, and if yes, when are you planning to do so? 6) Request for Re-use If your organisation does hold this information and is able to share it, then I would like to submit the following request for re-using the information:
Date of Response: 08/04/2025
View Response: 9882.pdf
Freedom of Information Request Reference: 9881
Date Received: 13/03/2025
Summary:
1. Is there any data on the prevalence and burden of chronic kidney disease available from your health board? 2. If so, how is it collected and what data is available?
Date of Response: 11/04/2025
View Response: 9881.pdf
Freedom of Information Request Reference: 9880
Date Received: 09/03/2025
Summary:
Who is the responsible person/service for the management of Ophthalmology dedicated phone number
Date of Response: 09/04/2025
View Response: 9880.pdf
Freedom of Information Request Reference: 9879
Date Received: 18/03/2025
Summary:
I am keen to understand how long patients are waiting for speech and language therapy. As such, for each financial year from 2019/20 to 2024/25 (most recent): 1. the total number of referrals for speech and language therapy, broken down by a) adult and b) children and young people? 2. both the median and longest wait from referral to an initial appointment/assessment, broken down by a) adult and b) children and young people? 3. both the median and longest wait from referral to starting treatment, broken down by a) adult and b) children and young people? 4. the total number of patients currently on a speech and language therapy waiting list, broken down by a) adult and b) children and young people?
Date of Response: 17/04/2025
View Response: 9879.pdf
Freedom of Information Request Reference: 9878
Date Received: 17/03/2025
Summary:
1. Does NHS Lothian require all GP practices operating in NHS premises to use health board telephony systems? 2. Are GP practices permitted to procure other technologies as an alternative to health board telephony systems? 3. With regard to the national BT switch from analogue to digital landlines, what efforts has the board made to ensure GP practices are aware that they do not require to install a new network and can use existing infrastructure to run cloud hosted telephony over? 4. If GPs are not allowed to use the existing network to run voice over, can the health board provide a reason this cannot be done via VLANs or segregation on the network? 5. What guidance has been provided to GP practices to support them to facilitate the switch in the most cost-effective and efficient manner? 6. Does NHS Lothian permit the recording of telephone calls between GP and patient? 7. If no, what assessment has been carried out of the potential benefits and risks of recording telephone conversations between GPs and patients? 8. What consideration has the board given to breaking down NHS buildings and services invoices to show telephony costs, providing greater transparency for GP practices regarding their expenses?
Date of Response: 14/04/2025
View Response: 9878.pdf
Freedom of Information Request Reference: 9877
Date Received: 08/03/2025
Summary:
Please include the following information for the following financial years: 2021/22, 2022/23, 2023/24, and 2024/25: • Total number of days lost due to sick leave taken by NHS Nurses • The total number of NHS nurses who took sick leave • Total number of days lost to Mental Health issues taken by NHS nurses • The total number of nurses who required sickness absence on mental health grounds • The number of NHS nurses taking more than seven days of absence without a sick note • The total number of days lost in excess of the seven days. • For example, if an individual has taken off 10 days without a sick note, then this would be 3 days in excess of the seven days
Date of Response: 14/04/2025
View Response: 9877.pdf
Freedom of Information Request Reference: 9876
Date Received: 17/03/2025
Summary:
Number of hospital admissions due to injuries caused by knife or bladed/pointed instrument/sharp objects in NHS Lothian broken down by area for the last three years, up to and including the latest available data.
Date of Response: 08/04/2025
View Response: 9876.pdf
Freedom of Information Request Reference: 9875
Date Received: 17/03/2025
Summary:
1. A breakdown of the number of NHS Lothian employees grouped by salary bands (e.g., £50,000–£55,000, £55,001–£60,000, etc.). 2. The number of NHS Lothian employees whose annual salary is £50,000 or higher. 3. The number of NHS Lothian employees whose annual salary is £80,000 or higher. 4. The number of NHS Lothian employees whose annual salary is £100,000 or higher.
Date of Response: 14/04/2025
View Response: 9875.pdf
Freedom of Information Request Reference: 9874
Date Received: 17/03/2025
Summary:
The number of unfilled clinical psychologists vacancies in NHS Lothian and what percentage of Clinical Psychologist vacancies are filled, meeting minutes where the financial burden of employing clinical psychologists was discussed in deciding the number of posts, and total spending on Trainee and Full Clinical Psychologists. Date range: Jan 1 2024- 14 March 2025
Date of Response: 14/04/2025
View Response: 9874.pdf
Freedom of Information Request Reference: 9873
Date Received: 17/03/2025
Summary:
Please provide me with the number of weight loss medication prescriptions which have been issued since 2022. Please provide stats by year. Please provide a breakdown of the various medications prescribed, including, but not limited to, Liraglutide (Saxenda®), Semaglutide (Wegovy®) and Tirzepatide.
Date of Response: 08/04/2025
View Response: 9873.pdf
Freedom of Information Request Reference: 9872
Date Received: 17/03/2025
Summary:
1. The numbers of patients who underwent surgery to repair an abdominal aortic aneurysm at the Edinburgh Royal Infirmary in years 2022, 2023 and 2024. 2. Of that yearly patient cohort the number who died within the 3, 6 and 12 month post op periods. 3. Of that yearly patient cohort how many experienced a spinal cord injury as a result of their surgery.
Date of Response: 08/04/2025
View Response: 9872.pdf
Freedom of Information Request Reference: 9871
Date Received: 14/03/2025
Summary:
I request details of any defective, unused, or written-off medical equipment purchased over the last five years, including: 1. The total value of medical equipment that was found to be defective or unfit for use. 2. A list of the defective or unused equipment, including: o The type of equipment o The supplier/manufacturer o The cost o The reason it was not used or found defective 3. Any costs associated with storage, maintenance, or disposal of this equipment.
Date of Response: 11/04/2025
View Response: 9871.pdf
Freedom of Information Request Reference: 9870
Date Received: 14/03/2025
Summary:
I request details of all spending on external consultants over the last five years, including: 1. The total amount spent each year on external consultancy services. 2. A list of all consultancy contracts awarded, including: o The name of the consultancy firm o The purpose of the contract o The cost of each contract o The outcome or deliverables provided
Date of Response: 09/04/2025
View Response: 9870.pdf
Freedom of Information Request Reference: 9868
Date Received: 14/03/2025
Summary:
Can you confirm if you still have an available pathway for diagnosis of adult Autism and ADHD? What criteria do you have for someone to be referred for diagnosis?
Date of Response: 11/04/2025
View Response: 9868.pdf
Freedom of Information Request Reference: 9866
Date Received: 13/03/2025
Summary:
Q.1 How many patients under the age of 18-years-old have received Electroconvulsive therapy in the past ten years, could you please provide this in a breakdown of financial years? Q.2 Could you please provide the total number of Electroconvulsive therapy session were used for under 18s in the past ten years, could you please provide this in a breakdown of financial years? To clarify, by session I am referring to each time ECT was used not the number of blocks. Q.3 What is the total number of adverse events recorded on DATIX as a result of ECT in under 18s in the past 10 years. Can you please provide this in a breakdown of the past ten financial years?
Date of Response: 10/04/2025
View Response: 9866.pdf
Freedom of Information Request Reference: 9865
Date Received: 13/03/2025
Summary:
Can I request the following information broken down by the calendar year for 2021, 2022, 2023, 2024, and 2025 (most recent as of this email). 1. How many X-Ray scanners have had an error, fault, or needed any non-planned engineer work? a. How many cumulative/total hours of X-Ray downtime has been caused by these issues ? 2. How many CT scanners have had an error, fault, or needed any non-planned engineer work a. How many cumulative/total hours of CT downtime has been caused by these issues? 3. How many MRI scanners have had an error, fault, or needed any non-planned engineer work a. How many cumulative/total hours of MRI downtime has been caused by these issues?
Date of Response: 02/04/2025
View Response: 9865.pdf
Freedom of Information Request Reference: 9864
Date Received: 13/03/2025
Summary:
Regarding policy surrounding surgical referrals made by clinicians at Chalmers Gender Identity Clinic in Edinburgh. 1. Is there any pause or restriction on patients being referred for surgery currently in effect? 2. Has there been any such pause or restriction in effect since 1 January 2024? 3. If the answer to 1 or 2 is yes, please provide the start and (if applicable) end date or expected end dates for the pause or restriction. 4. If the answer to 1 or 2 is yes, please provide all communications, minutes, agendas and policy documents which include mention of the pause or restriction, from a time period of six months before the start of the pause or restriction to the present day.
Date of Response: 09/04/2025
View Response: 9864.pdf
Freedom of Information Request Reference: 9863
Date Received: 09/03/2025
Summary:
The amount of funds spent by the Health Board to deliver the National Dental Inspection Programme in 2024-25 to date. The amount of funds spent by the Health Board to deliver the National Dental Inspection Programme for the four previous financial years.
Date of Response: 21/03/2025
View Response: 9863.pdf
Freedom of Information Request Reference: 9862
Date Received: 09/03/2025
Summary:
The number of delayed discharges in 2024/25 resulting from issues of patients who lack capacity but do not have a person appointed with the Power of Attorney.
Date of Response: 09/04/2025
View Response: 9862.pdf
Freedom of Information Request Reference: 9861
Date Received: 12/03/2025
Summary:
1. How many care homes are operated by the NHS in your health board? 2. How care homes, operated by the NHS in your health board, have closed in the last five years? (please can you split this up by year). 3. How many care homes, operated by the NHS in your health board, have temporarily closed in the last five years? (please can you split this up by year). 4. Could you provide any information on the reasons for why those homes were closed or temporarily closed?
Date of Response: 09/04/2025
View Response: 9861.pdf
Freedom of Information Request Reference: 9859
Date Received: 12/03/2025
Summary:
I would like to request the following data: •The current average waiting time for an initial autism assessment appointment in your health board area. •The number of adult referrals from GPs for an initial autism assessment in 2024, broken down by gender.
Date of Response: 04/04/2025
View Response: 9859.pdf
Freedom of Information Request Reference: 9858
Date Received: 01/03/2025
Summary:
Q1. Please provide the total number of patients treated in the last 6 months for: •Polycythaemia Vera (ICD10 code D45) •Myelofibrosis (ICD10 code D47.4) •Myelofibrosis (ICD10 code D47.4) patients aged 65 and older Q2. How many patients were treated in the past 6 months (for any disease) with: •Ruxolitinib •Fedratinib •Momelotinib Q3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases? •Myelofibrosis (ICD10 code D47.4) •Polycythaemia Vera (ICD10 code D45) •Other/Unknown Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? •Of these patients, how many were treated in the past 6 months with Hydroxycarbamide? •Of these patients, how many were treated in the past 6 months with Interferon therapy? •Of these patients, how many have received no active treatment in the past 6 months? Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.
Date of Response: 07/04/2025
View Response: 9858.pdf
Freedom of Information Request Reference: 9857
Date Received: 11/03/2025
Summary:
I would be grateful if you could provide me with a hard copy of NHS Lothian's extravasation policy and procedure as in force on 5 March 2024.
Date of Response: 08/04/2025
View Response: 9857.pdf
Freedom of Information Request Reference: 9856
Date Received: 11/03/2025
Summary:
Q1. In the past 3 months, how many patients have received the following treatments (for any disease): • Berinert (Human C1-esterase inhibitor) • Cinryze (Human C1-esterase inhibitor) • Firazyr (Icatibant) • Icatibant - any brand except Firazyr • Orladeyo (Berotralstat) • Ruconest (Recombinant human C1-esterase inhibitor) • Takhzyro (Lanadelumab) • Garadacimab (Andembry) Q2. In the past 3 months how many patients have received the following immunoglobulin treatments (for any disease): • Cutaquig • Cuvitru • Gammagard • Gammanorm • Hizentra • Hyqvia • Intratect • Iqymune • Kiovig • Privigen • Octagam • Panzyga • Subgam • Any other normal immunoglobulin
Date of Response: 04/04/2025
View Response: 9856.pdf
Freedom of Information Request Reference: 9855
Date Received: 11/03/2025
Summary:
Can I request the following, broken down by the calendar years 2019, 2023, 2024 and 2025 (most recent): 1. The median wait (in days) between the initial meeting (assessment/choice appointment), where a CAMHS professional will talk to the child or young person who is unwell, listen to their symptoms and decide on how to help them, and the start of treatment. 2. The longest wait (in days) between the initial meeting (assessment/choice appointment), where a CAMHS professional will talk to the child or young person who is unwell, listen to their symptoms and decide on how to help them, and the start of treatment.
Date of Response: 11/04/2025
View Response: 9855.pdf
Freedom of Information Request Reference: 9854
Date Received: 11/03/2025
Summary:
1. How many pharmacists are registered as Independent Prescribers (IP’s) in your Health Board? 2. How does your Health Board assess if a prescriber is active or not? 3. How many pharmacists are registered as active Independent Prescribers (IP’s) in your Health Board? 4. How many pharmacist Independent Prescribers (IP’s) are actively working within each sector in your Health Board? Please specify sector and number of prescribers within each. Sector Number of active Pharmacist IP's Hospital inpatient Hospital outpatient GP practices Community pharmacies Other (please specify sector) 5. What therapeutic/clinical areas are pharmacist Independent Prescribers (IP’s) practising within? Please specify number of pharmacist IP’s within each therapeutic/clinical area. Therapeutic/Clinical Area Number of active Pharmacist IP's Cardiovascular (hypertension, heart failure, ischaemic heart disease, dyslipidaemia) Common clinical conditions (respiratory tract, ENT, skin, UTI) Endocrinology (thyroid dysfunction, diabetes mellitus) Gastrointestinal (peptic ulcer disease, gastro-oesophageal reflux disease, inflammatory bowel disease) Musculoskeletal (osteoarthritis, rheumatoid arthritis, pain) Neurology (Alzheimer’s disease, epilepsy, Parkinson’s) Oncology (general aspects, breast cancer, colorectal cancer, lung cancer) Psychiatry (affective disorders, anxiety and sleep, schizophrenia) Respiratory (asthma, chronic obstructive pulmonary disease) Women’s Health (HRT, menstrual, endometriosis) Non-specialist (general practice across multiple sectors) Other (please specify therapeutic area) 6. How many pharmacists in your Heath Board are currently undertaking independent prescribing training? 7. How many pharmacists in your Health Board are waiting to access independent prescribing training?
Date of Response: 04/04/2025
View Response: 9854.pdf
Freedom of Information Request Reference: 9852
Date Received: 11/03/2025
Summary:
Can you tell me what criteria is used or what the reason could be for shorter wait time to see a consultant which resulted in a referral to the waiting list 2 months before me? We are both part of NHS Lothian albeit living in different council areas. What is the average wait time from GP referral to the point of being added to the waiting list for hip replacement by council area within NHS Lothian? What is the criteria which determines the waiting time for an orthopaedic consultation? Why would it be different in some cases?
Date of Response: 04/04/2025
View Response: 9852.pdf
Freedom of Information Request Reference: 9851
Date Received: 12/03/2025
Summary:
Question One Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment Question Two How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments: Atezolizumab (Tecentriq) Avelumab (Bavencio) Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Nivolumab (Opdivo) Cisplatin with Gemcitabine + Avelumab (Bavencio) Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) Nivolumab (Opdivo) Pembrolizumab (Keytruda) Other active systemic anti-cancer therapy Palliative care only Erdafitinib Question Three How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies: Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Avelumab (Bavencio) Question Four Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Date of Response: 04/04/2025
View Response: 9851.pdf
Freedom of Information Request Reference: 9818
Date Received: 04/03/2025
Summary:
How many people have left the waiting lists for hip or knee replacements in each year since 2020 (by calendar year) and for what reason? This means, a person was on the waiting list but left it or was removed before getting a procedure. Please separate the data by each procedure.
Date of Response: 17/04/2025
View Response: 9818.pdf
Freedom of Information Request Reference: 9850
Date Received: 10/03/2025
Summary:
I would be grateful if you could provide the following information for the most recent financial year available: 1. The total spending by the ICB on outpatient psychiatry appointments. 2. The average cost per assessment/appointment for the following outpatient psychiatry services: - ADHD assessments - Autism Spectrum Disorder (ASD) assessments - General mental health assessments - Drug and alcohol assessments - Child psychiatry assessments - Follow-up psychiatry appointments 3. If available, a breakdown of the above costs distinguishing between assessments carried out by NHS providers and those commissioned from private providers.
Date of Response: 02/04/2025
View Response: 9850.pdf
Freedom of Information Request Reference: 9849
Date Received: 10/03/2025
Summary:
I would like to put in a Freedom of information request for all notes of interest for pharmacies in Lothian. I would also like to know the exact location/area of each note of interest. I would also like to request the timeline for each note of interest i.e timeline for when they will proceed to pre application meeting.
Date of Response: 07/04/2025
View Response: 9849.pdf
Freedom of Information Request Reference: 9848
Date Received: 10/03/2025
Summary:
I am writing to formally request information regarding communication systems used by NHS Lothian for communicating with patients not attending face-to-face outpatient appointments. The information requested is as follows : - 1. Policy and Procedure - Please provide a copy of NHS Lothian’s current policy and procedure on the use of telephone and online appointments, including video call systems. - Please confirm the name of all video call systems currently in use by NHS Lothian e.g. Microsoft Teams, Near Me etc. 2. Near Me system • When was the Near Me video call system first introduced in NHS Lothian? • What training programs or resources have been provided to staff to ensure they are adequately trained in using the Near Me system? • How is the effectiveness of this training evaluated? • Is there ongoing training or support systems in place for new staff and/or to provide refresher training? 3. Challenges and Lessons Learned • What have been the biggest challenges in implementing and adopting the Near Me system within NHS Lothian? 4. Staff Engagement and Buy-In • How was staff engagement ensured during the planning and implementation phases of the Near Me system? • Is there universal buy-in from all staff (including medical staff, nursing staff, admin. Staff etc) regarding the use of the Near Me system? If not, what are the main concerns or resistance points? • Have staff reported any challenges or barriers in using the Near Me system, and how have these been addressed? 4. Exemptions • - Are all departments expected to offer patients a consultation via Near Me, where the same appointment is able to offered as a telephone option for the same consultation? • Are there any outpatient departments within NHS Lothian that are currently allowed to not use video call systems, where a telephone appointment can be made available? • If so, please list these departments and provide the rationale for this exemption. 5. Principles of Use • What were the primary drivers or motivations for adopting the Near Me system within NHS Lothian? • What are NHS Lothian’s principles for using telephone and online appointment systems, particularly in relation to ensuring accessibility for disabled people and those who are unemployed? • Are there any specific measures in place to support these groups in accessing appointments via these systems? 6. Online Information - Please provide links to any information available online about NHS Lothian’s use of telephone and online appointment systems, including video calls.
Date of Response: 07/04/2025
View Response: 9848.pdf
Freedom of Information Request Reference: 9847
Date Received: 10/03/2025
Summary:
• How many Osteotomies have been conducted within your Health Board over the last five years. • What is the average length of wait for such a procedure within this time period? • What are the number of Osteotomies conducted as a result of broken bones which have been left untreated (i.e., how many Osteotomies are conducted on people who have recent - say in the last three years - previous broken bones).
Date of Response: 08/04/2025
View Response: 9847.pdf
Freedom of Information Request Reference: 9846
Date Received: 10/03/2025
Summary:
Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: •Atezolizumab (Tecentriq) •Durvalumab (Imfinzi) •Nivolumab (Opdivo) •Pembrolizumab (Keytruda) •Chemotherapy •Radiotherapy •Chemotherapy AND Radiotherapy •Osimertinib Q2. How many patients were treated in the past 3 months for gastric cancer (any stage) with: •CAPOX (Capecitabine with Oxaliplatin) •FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) •Lonsurf (Trifluridine - tipiracil) •Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) •Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) •Any other systemic anti-cancer therapy •Palliative care only •Zolbetuximab (Vyloy) Q3 How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with: •CAPOX (Capecitabine with Oxaliplatin) •FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) •Lonsurf (Trifluridine - tipiracil) •Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) •Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) •Zolbetuximab (Vyloy) •Any other systemic anti-cancer therapy •Palliative care only Q4 How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction? Q5. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?
Date of Response: 04/04/2025
View Response: 9846.pdf
Freedom of Information Request Reference: 9844
Date Received: 07/03/2025
Summary:
Questionnaire related to wound care.
Date of Response: 04/04/2025
View Response: 9844.pdf
Freedom of Information Request Reference: 9843
Date Received: 06/03/2025
Summary:
I require you to review your response.
Date of Response: 09/04/2025
View Response: 9843.pdf
Freedom of Information Request Reference: 9845
Date Received: 07/03/2025
Summary:
How many individuals are currently open to NHS Lothian's Forensic Community Mental Health Team? Of those currently open to the team, how many are aged 50 or older?
Date of Response: 09/04/2025
View Response: 9845.pdf
Freedom of Information Request Reference: 9842
Date Received: 06/03/2025
Summary:
1. In each year since 2019-20, including the current year to date, in this health board, how many patients have been directed or referred to hospitals or other healthcare settings (clinics/primary care centres etc) in another health board? 2. In relation to Q1, what was the furthest transfer in miles? 3. In relation to Q1, is there a cost associated with this?
Date of Response: 09/04/2025
View Response: 9842.pdf
Freedom of Information Request Reference: 9841
Date Received: 06/03/2025
Summary:
• What hospitals are a part of your Trust / Health Board? • Do any of these have Pathology Labs and if so which? • Which of the National Pathology Networks do you belong to? • Do you partner with any other Labs to work collectively? • What Laboratory Information Management systems (LIMS / LIS) do you use? • Do you have a Single instance / Pathology Network Wide LIS / LIMS solution? • When is the contract for your LIS / LIMS due to run out? • Do you have a Blood Transfusion Laboratory at any of your locations and if so which? • Do you have an Electronic Blood Tracking solution? • Do you have a dedicated Transfusion Lab LIS / LIMS and if so which? • Do you have anyone leading on Digital Transformation projects and if so who (if not able to state a name, what is their Role / Job title)?
Date of Response: 03/04/2025
View Response: 9841.pdf
Freedom of Information Request Reference: 9840
Date Received: 06/03/2025
Summary:
1. How much has your organisation spent on measures relating to Equality, Diversity and Inclusion in each year since 2019-20? 2. In relation to Q1, please provide as much information on what this money has been spent on?
Date of Response: 01/04/2025
View Response: 9840.pdf
Freedom of Information Request Reference: 9839
Date Received: 06/03/2025
Summary:
Please can you send me: • A copy of the guidelines for GPs to refer patients with suspected ILD to specialist respiratory services. • A copy of your board’s ILD diagnosis pathway. • Information about ILD MDT meetings held by clinicians in your Board areas, including: o Which professionals attend ILD MDT meetings. o The schedule for holding of ILD MDT meetings. o The number of patients considered at each ILD MDT meeting. o The number of patients marked “suspected ILD” who have been referred to an ILD MDT in each of the past three years. • The number of the following healthcare professionals currently working in the health board, and the site where they are based: o medical consultants and registrars with stated specialism in ILD (including but not limited to radiology and respiratory) o ILD specialist nurses o ILD specialist pharmacists o ILD specialist physiotherapists • The number of antifibrotic prescriptions initiated for patients living in your NHS board areas in each of the last three years.
Date of Response: 03/04/2025
View Response: 9839.pdf
Freedom of Information Request Reference: 9838
Date Received: 05/03/2025
Summary:
For the last three years, where data is available, please could you confirm the following: 1. The total amount spent by the board on providing a public dental service, broken down by year. 2. The number of full time equivalent dentists employed by the health board to provide PDS, broken down by year. 3. The number of proceduress carried out by the PDS, broken down by year, if known. 4. The number of patients treated by the PDS, broken down by year, if known. 5. Details of the locations where PDS services are currently provided. 6. The number of referrals and waiting list size, broken down by year, if known.
Date of Response: 02/04/2025
View Response: 9838.pdf
Freedom of Information Request Reference: 9837
Date Received: 05/03/2025
Summary:
I would like to request information regarding your obstetric unit(s) in your NHS board, under the FOIA, -Is your Hospital a tertiary Fetal Medicine Unit? -Does your Hospitals do a routine late third trimester scan for every woman in pregnancy? Regarding growth scans in the second or third trimester: -To calculate HC do you use HC or BPD + OFD? -To calculate AC do you use AC or TAPD + APD? -To plot FL centile which biometry chart do you use? (eg Chitty ) -To plot HC centile which biometry chart do you use? (eg Chitty ) -To plot AC centile which biometry chart do you use? (eg Chitty ) -What algorithm do you use to calculate Estimated Fetal Weight? (Eg Hadlock (HC, AC, FL), Hadlock (BPD-HC-AC-FL), Hadlock (FL-AC), Warsof (BPD-AC), Persson (BPD-TAD-APAD-FL), Hansmann et al, Combs, Souka, INTERGROWTH-21ST or other) -What centile reference chart do you use to plot the Estimated Fetal Weight? -Does your trust use GAP-GROW? -To measure Amniotic Fluid does your trust measure Deepest Vertical Pool or measure Amniotic Fluid Index? -Which chart do you use to plot the amniotic fluid volume? -When measuring Uterine Artery Doppler PI and PSV which reference centile chart do you use? -When measuring Umbilical Artery Doppler PI and PSV which reference centile chart do you use? -When measuring Middle Cerebral Artery Doppler PI and PSV which reference centile chart do you use? -When measuring Ductus Venosus Doppler PI and PSV which reference centile chart do you use?
Date of Response: 02/04/2025
View Response: 9837.pdf
Freedom of Information Request Reference: 9836
Date Received: 05/03/2025
Summary:
Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments? Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: •Dostarlimab (Jemperli) •Dostarlimab (Jemperli) AND Chemotherapy •Hormone therapy (Progesterone or Letrozole) •Pembrolizumab (Keytruda) monotherapy •Lenvatinib + Pembrolizumab (Lenvima +Keytruda)  •Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) •Any other SACT •Any other Chemotherapy •Durvalumab with platinum-based chemotherapy •Pembrolizumab with platinum-based chemotherapy Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy? Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: •Dostarlimab (Jemperli) AND Chemotherapy •Durvalumab with platinum-based chemotherapy •Pembrolizumab with platinum-based chemotherapy •Hormone therapy (Progesterone or Letrozole) •Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) •Any other SACT •Any other chemotherapy Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Date of Response: 02/04/2025
View Response: 9836.pdf
Freedom of Information Request Reference: 9831
Date Received: 05/03/2025
Summary:
1. The number of audiology staff employed by the board in 2022, 2023, 2024 and 2025 to date. 2. The number of people placed on an audiology appointment waiting list in 2022, 2023, 2024 and 2025 to date. 3. The a/ average and b/ longest waiting times for the audiology service in 2022, 2023, 2024 and 2025 to date.
Date of Response: 15/04/2025
View Response: 9831.pdf
Freedom of Information Request Reference: 9804
Date Received: 28/02/2025
Summary:
I wish to make a Freedom of Information Request for the organisations single sex patient changing, toilet & showering policy.
Date of Response: 15/04/2025
View Response: 9804.pdf
Freedom of Information Request Reference: 9834
Date Received: 05/03/2025
Summary:
I wish to raise a Freedom of Information Request to cover Hospital guidance/training to staff on POAs Please advise what training/guidance is provided to staff regarding the recording of a Power of Attorney (POA) when approached by a relative/friend of a patient with the necessary POA authority. In addition, is there any additional training/guidance provided for POAs with non standard clauses e.g. when the POA document gives the Attorney the authority to declare the patient as no longer having capacity?
Date of Response: 02/04/2025
View Response: 9834.pdf
Freedom of Information Request Reference: 9833
Date Received: 05/03/2025
Summary:
1. Please provide the number of people waiting for an NHS assessment for ADHD and ADD in Edinburgh, Midlothian, West Lothian, and East Lothian a. Please break this down by number in each council area b. Please also provide the number of people on the waitlist at the end of each calendar year from 2019 to 2024 c. Please break down whether the person is waiting for an ADHD or ADD assessment. 2. Please provide the current estimated wait time (in years) for each council area. 3. How many NHS assessments for ADHD are being carried out each year in Edinburgh, Midlothian, West Lothian, and East Lothian? a. Please break this down by the number of assessments carried out each year in each area from 2019-2024 (inclusive).
Date of Response: 07/03/2025
View Response: 9833.pdf
Freedom of Information Request Reference: 9832
Date Received: 05/03/2025
Summary:
1. A copy of the the Orgnanisation's governance guidance document(s) regarding training of all employees in data protection and patient confidentiality. I understand this may have changed over time, please provide any documents showing changes or updates in the last 10 years, where that date range is not possible please provide what you can and clarify reasons why unable to provide more historical data (for example if this is due to a data retention policy then please include a copy of that data retention policy). 2. Information from the Organisation detailing the titles of roles (both clinical and non-clinical) and the data protection training and patient confidentiality training. For each role can you detail: a) expectations on candidates for employment and b) the frequency of renewal/refresh of such training for that title/role. If you do not have specific data, could you provide information on the general areas of roles... such as 'Nurses', 'Consultants', 'Surgeons', 'Secretary non-clinical', 'Payroll', etc, etc. This may have changed from year to year, over time - if this has changed significantly in the last 10 years, please advise of the date when changes were brought in and any associated documents regarding the change. 3. Information from the Organisation detailing the total number of staff and the percentage of adherence to completion of regular (annual?) renewal of data protection and patient confidentiality training. Please show as a trend over a number of years (annual aggregation is acceptable which shows the total staff and adherence/compliance data), Please provide data for the last 10 years, if unable to satisfy then provide it as far back as you can with a note on why additional historical data is not held (retention policy - then please quote the retention policy document). 4. Information from the Organisation regarding the number of data breaches. Grouped by those reported to the ICO (Information Commissioners Office) and those not reported to the ICO but reported internally to the organisation. If you could also provide within that data the severity that a breach was considered to be (e.g. Low, Medium, High). Additionally if any financial fines needed to be paid by the organisation, or other sanctions/enforcement actions made by the ICO or other regulatory body as a result of the breach. Please provide data for the last 10 years, if unable to satisfy then provide it as far back as you can with a note on why additional historical data is not held (retention policy - then please quote the retention policy document) 5. Please advise if your Organisation is asked to report on compliance with data protection training / patient confidentiality to a parent body or other organisation.
Date of Response: 02/04/2025
View Response: 9832.pdf
Freedom of Information Request Reference: 9830
Date Received: 05/03/2025
Summary:
I am aware NHS Lothian holds the HEPMA data recording system that The State Hospital is able to access. Please tell me for each year from 2019 to 2025: • How many PRNs were administered to the non-learning disabled/autistic population of The State Hospital? • How many of these were doses of benzodiazepines? • How many PRNs were administered to the -learning disabled/autistic population of The State Hospital? • How many of these were doses of benzodiazepines?
Date of Response: 01/04/2025
View Response: 9830.pdf
Freedom of Information Request Reference: 9829
Date Received: 05/03/2025
Summary:
Request in relation to personal information.
Date of Response: 26/03/2025
View Response: 9829.pdf
Freedom of Information Request Reference: 9828
Date Received: 04/03/2025
Summary:
I am seeking the number of referrals made to the CWIC mental health service in Haddington from 1st April 2020 to 1st April 2025.
Date of Response: 08/04/2025
View Response: 9828.pdf
Freedom of Information Request Reference: 9825
Date Received: 04/03/2025
Summary:
Stool Tests: 1. Are a) quantitative faecal immunochemical test and b) faecal calprotectin tests available in primary care in your area and for what indications? 2. If they are not available, please list the area(s) where faecal calprotectin tests is unavailable. Diagnostic Pathways: 3. How many diagnostic pathways do you currently have for patients presenting with Lower gastrointestinal symptoms? 4. Please can you list the titles of the pathways 5. Which of these pathways include the usage of faecal calprotectin test?
Date of Response: 01/04/2025
View Response: 9825.pdf
Freedom of Information Request Reference: 9824
Date Received: 04/03/2025
Summary:
I would like to request the following information regarding the ophthalmology services and IT systems used within your Trust: Ophthalmology Department & IT Record System 1. Does your Trust have an ophthalmology department and/or provide ophthalmology clinics? 2. If so, what is the name of the principal IT record system used to document results from patient consultations within ophthalmology? Imaging Capabilities & System Integration 3. Does the principal IT system allow clinicians to view images from scans conducted during a clinic visit? 4. Are there any types of medical images that cannot be imported into this principal IT system? If so: • What is the name of the IT programme used by clinicians to view these images? • What is the name of the scan/modality that generates these images? Data Integration with National Systems 5. Does the principal IT system integrate with the NHS Spine or other national patient record systems (e.g., OpenEyes, Medisoft, Epic)? 6. Does the system support the exchange of structured data with other NHS Trusts or external healthcare providers? Patient Access & Communication 7. Does the system allow patients to access their ophthalmology records, including images, via the NHS App or another patient portal? 8. Are there any restrictions on how imaging data can be shared with patients and external providers? Image Storage & Viewing Capabilities 9. What is the storage capacity and retention policy for ophthalmology-related imaging within the IT system? 10. If images are not viewable within the principal IT system, does the Trust use a separate PACS (Picture Archiving and Communication System) for ophthalmology imaging? Future IT Developments & Interoperability 11. Is the Trust planning any upgrades or changes to its ophthalmology IT infrastructure in the next five years? 12. Are there known interoperability challenges that affect the transfer of ophthalmology data within the Trust or between NHS organizations?
Date of Response: 09/04/2025
View Response: 9824.pdf
Freedom of Information Request Reference: 9823
Date Received: 04/03/2025
Summary:
Please see the below with regard to the Astley Ainslie move to Haddington. When did discussions about relocating patients start? Who within NHS Lothian knew about this relocation?
Date of Response: 09/04/2025
View Response: 9823.pdf
Freedom of Information Request Reference: 9814
Date Received: 04/03/2025
Summary:
BREAST CANCER Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available? 1.1 Abemaciclib (Verzenios) 1.2 Alpelisib (Piqray) 1.3 Elacestrant (Orserdu) 1.4 Fulvestrant (fulvestrant or Faslodex) 1.5 Inavolisib (Inaqovi) 1.6 Palbociclib (Ibrance) 1.7 Ribociclib (Kisqali) 1.8 Capivasertib (Truqap) 1.9 Talazoparib (Talzenna) 1.10 Olaparib (Lynparza) Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available? 2.1 Abemaciclib (Verzenios) 2.2 Ribociclib (Kisqali) 2.3 Olaparib (Lynparza) Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period for which data are available? 3.1 Abemaciclib (Verzenios) 3.2 Ribociclib (Kisqali) Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-month period available? 4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) 4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) 4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of October 2024 to the end of December 2024? 5.1 All types of breast cancer 5.2 Locally advanced or metastatic breast cancer ENDOMETRIAL CANCER Q6. How many patients were treated for Endometrial Cancer, with the following medicines in the 3 months between 1st October 2024 and 31st December 2024, or latest 3-months for which data are available? 6.1 Dostarlimab (Jemperli) 6.2 Pembrolizumab (Keytruda) 6.3 Lenvatinib (Lenvima) Q7. How many patients were treated for Endometrial Cancer, with the following medicines as monotherapy or in combination, in the 3 months between 1st October 2024 and 31st December 2024, or latest 3-months for which data are available? 7.1 Dostarlimab monotherapy 7.2 Dostarlimab in combination with Chemotherapy 7.3 Pembrolizumab monotherapy 7.4 Pembrolizumab + Lenvatinib in combination 7.5 Lenvatinib monotherapy
Date of Response: 25/03/2025
View Response: 9814.pdf
Freedom of Information Request Reference: 9780
Date Received: 24/02/2025
Summary:
1. Does your Health Board have a patient flow system? 2. If so, is it using the electronic patient record, Or the national offer built on Palantir/Foundry? 3. Or does the Health Board have a specialist flow product? If so, what is the • Supplier name • System name • Contract expiry date
Date of Response: 09/04/2025
View Response: 9780.pdf
Freedom of Information Request Reference: 9772
Date Received: 19/02/2025
Summary:
1. The total number of asbestos cement pipes in NHS properties, and in which properties they are found 2. Whether there were any asbestos cement pipes present in the Princess Alexandra Eye Pavilion prior to its closure for repairs 3. If the answer to question 2 is yes, was the presence of asbestos cement pipes a factor in the decision to close the Princess Alexandra Eye Pavilion for repairs
Date of Response: 08/04/2025
View Response: 9772.pdf
Freedom of Information Request Reference: 9819
Date Received: 04/03/2025
Summary:
I would like to request the following details regarding the ambulatory ECG monitoring service across the hospitals within your Health Board: 1. The number of ambulatory ECG monitors fitted at each hospital within the Health Board in 2024. 2. The manufacturer(s) of ambulatory ECG monitors used at each hospital. 3. The current waiting times for patients to have an ambulatory ECG monitor fitted at each hospital. 4. The number of patients currently on the waiting list for ambulatory ECG monitoring at each hospital. 5. The number of ambulatory ECG recordings awaiting analysis at each hospital. 6. The current wait time for an ECG recording to be analysed once the patient has returned the monitor at each hospital. 7. The target timeframe within which each hospital aims to analyse routine ECG recordings after the monitor is returned.
Date of Response: 02/04/2025
View Response: 9819.pdf
Freedom of Information Request Reference: 9817
Date Received: 04/03/2025
Summary:
1. The name, job title and email address of the individual responsible for outpatients waiting times? 2. The name, job title and email address of the individual responsible for day case/inpatients waiting times? 3. The name, job title and email address of the individual responsible for medical staff recruitment? 4. The name, job title and email address of the individual responsible for AHP recruitment? 5. The name, job title and email address of the individual responsible for nursing staff recruitment? 6. The name, job title and email address of the individual responsible diagnostic waiting times?
Date of Response: 27/03/2025
View Response: 9817.pdf
Freedom of Information Request Reference: 9815
Date Received: 04/03/2025
Summary:
MYELOPROLIFERATIVE DISEASES Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 1.1 Fedratinib (Inrebic) 1.2 Momelotinib (Omjjara) 1.3 Ruxolitinib (Jakavi) 1.4 Hydroxycarbamide Q2. How many patients were treated for the following myeloproliferative diseases in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? Diagnosis with ICD10 codes 2.1 Polycythaemia vera ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3 2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3 2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3 2.4 Myeloproliferative Disease, Chronic ICD10 code = D471, D47.1 Q3. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 3.1 Ruxolitinib (Jakavi) 3.2 Hydroxycarbamide Q4. How many patients with Polycythaemia Vera (ICD10 codes = D45, D450, D45.0, D45X OR morphology code = 9950/3) were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 4.1 Ruxolitinib (Jakavi) 4.2 Hydroxycarbamide NON-HODGKIN’S LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND ACUTE MYELOID LEUKAEMIA (AML) Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 5.1 Acalabrutinib (Calquence) 5.2 Ibrutinib (Imbruvica) 5.3 Pirtobrutinib (Jaypirca) 5.4 Venetoclax (Venclyxto) 5.5 Zanubrutinib (Brukinsa) 5.6 Rituximab 5.7 Obinutuzumab (Gazyvaro) Q6. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 6.1 Acalabrutinib (Calquence) 6.2 Ibrutinib (Imbruvica) 6.3 Pirtobrutinib (Jaypirca) 6.4 Venetoclax (Venclyxto) 6.5 Zanubrutinib (Brukinsa) 6.6 Obinutuzumab (Gazyvaro) 6.7 Rituximab 6.8 Bendamustine 6.9 Chlorambucil 6.10 Fludarabine 6.11 Cyclophosphamide Q7. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 7.1 Ibrutinib + venetoclax 7.2 Obinutuzumab + venetoclax 7.3 Zanubrutinib monotherapy / maintenance 7.4 Ibrutinib monotherapy / maintenance 7.5 Venetoclax monotherapy 7.6 Venetoclax + rituximab Q8. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 8.1 Acalabrutinib 8.2 Ibrutinib 8.3 Zanubrutinib Q9. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 9.1 Azacitidine 9.2 Cytarabine 9.3 Venetoclax (Venclyxto) Q10. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of October 2024 and end of December 2024, or latest 3-month period available? 10.1 Venetoclax + Azacitidine (with or without posaconazole) 10.2 Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)
Date of Response: 01/04/2025
View Response: 9815.pdf
Freedom of Information Request Reference: 9813
Date Received: 28/02/2025
Summary:
How many items of PPE have been held by your health board for each of the past six years? How many items are currently held? What procedures/policy does your health board currently have in place in regards to storing PPE for any future pandemic?
Date of Response: 26/03/2025
View Response: 9813.pdf
Freedom of Information Request Reference: 9812
Date Received: 03/03/2025
Summary:
Please can you open an internal review into this? I write in response to your request for information in relation to properties sold by NHS Lothian.
Date of Response: 27/03/2025
View Response: 9812.pdf
Freedom of Information Request Reference: 9811
Date Received: 03/03/2025
Summary:
• What is your health board’s policy on access to single-sex spaces and can you please send a copy of that policy to me? • Do female staff have routine access to single-sex spaces and facilities, specifically changing facilities?
Date of Response: 04/04/2025
View Response: 9811.pdf
Freedom of Information Request Reference: 9810
Date Received: 03/03/2025
Summary:
• Does the Trust have a contract of any kind in place with any agency for the provision of temporary non-medical and non-clinical workers? • If yes to the above question, who is the contract with, when was the contract awarded and when does it expire? • Which framework does the Trust use to hire agency workers? • How much did the Trust spend on agency workers falling into the category of non-medical and non-clinical for the period: o April 2022 to March 2023 o April 2023 to March 2024 • Who is the person responsible for (or would be responsible for) awarding temporary staffing contracts for the Trust? (Please provide the full name, job title and work email).
Date of Response: 28/03/2025
View Response: 9810.pdf
Freedom of Information Request Reference: 9809
Date Received: 03/03/2025
Summary:
PROSTATE CANCER Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available? 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel (Jevtana or generic cabazitaxel) 1.4 Darolutamide (Nubeqa) 1.5 Enzalutamide (Xtandi) 1.6 Talazoparib (Talzenna) 1.7 Docetaxel Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available? 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer Q3. How many patients were treated with the following combinations in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available? 3.1 Darolutamide (Nubeqa) + Docetaxel + ADT 3.2 Olaparib (Lynparza) + Abiraterone Q4. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st October 2024 to the end of December 2024, or latest 3-months for which data are available? 4.1 Abiraterone 4.2 Enzalutamide NIVOLUMAB Q5. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-months for which data are available? 5.1 Nivolumab (Opdivo) 5.2 Nivolumab/Relatlimab (Opdualag) Q6. How many patients were treated with Nivolumab (Opdivo) for the following diagnoses in the 3 months between the start of October 2024 to the end of December 2024, or latest 3-months for which data are available? 6.1 Malignant melanoma (ICD-10 codes = C43*, C44*, D03*, D485) 6.2 Lung Cancer (ICD-10 codes = C34*, C780) 6.3 Mesothelioma (ICD-10 codes = C45*, C384, C782) 6.4 Renal Cell Carcinoma (ICD-10 codes = C64*, C65*, C790, D410) 6.5 Oesophageal or Gastro-Oesophageal Junction (ICD-10 codes = C15*) 6.6 Hodgkin Lymphoma (ICD-10 codes = C81*) 6.7 Head and Neck Cancer (ICD-10 codes = C00 to C14, C30 to C32, C760, C770) 6.8 Urothelial Carcinoma (ICD-10 codes = C67*) 6.9 Colorectal Cancer (ICD-10 codes = C18 to C20)
Date of Response: 02/04/2025
View Response: 9809.pdf
Freedom of Information Request Reference: 9808
Date Received: 03/03/2025
Summary:
How many patients were treated in February 2025 (or latest available month) by the Dermatology department with the following drugs: •Abrocitinib (Cibinqo) •Baricitinib (Olumiant) •Dupilumab (Dupixent) •Lebrikizumab (Ebglyss) •Omalizumab (Xolair) •Tralokinumab (Adtralza) •Upadacitinib (Rinvoq) •Nemolizumab (Nemluvio) How many patients were treated in February 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs: •Benralizumab (Fasenra) •Dupilumab (Dupixent) •Mepolizumab (Nucala) •Omalizumab (Xolair) •Reslizumab (Cinqaero) •Tezepelumab (Tezspire)
Date of Response: 03/04/2025
View Response: 9808.pdf
Freedom of Information Request Reference: 9807
Date Received: 03/03/2025
Summary:
Please explain how the KTE Job Evaluation points would be lower for a Health Visitor Team Manager than for a Health Visitor. I'm keen to know if the NHS Lothian Job Evaluation process is logical and consistent. Is NHS Lothian Job Evaluation just making it up as they go along?
Date of Response: 02/04/2025
View Response: 9807.pdf
Freedom of Information Request Reference: 9805
Date Received: 28/02/2025
Summary:
Regarding the insulin pump waiting times, “Over 1000 on waiting list - is this 1001 or 1999 or even higher? “Longest wait up to 39 months - what is the statistical trend? For example, how many insulin pumps have been supplied in 2020, 2021, 2022, 2023 and 2024? How many are budgeted to be supplied in 2025? How many are projected to be supplied in 2026, 2027, 2028? “Exponential growth in demand - the only way to be in a position to describe growth as exponential is to have the underlying data behind it so, what is still data? “All other statements in the response are no better than best endeavours and taken as read because we all want to do better. “As I said previously the current eight year wait is a direct quote from the medical team on the ground at the Western General, nothing in the response from NHS Lothian provides reassurance otherwise.”
Date of Response: 01/04/2025
View Response: 9805.pdf
Freedom of Information Request Reference: 9803
Date Received: 26/02/2025
Summary:
• The number of cases of dental sepsis that have been treated at the health board's Accident and Emergency - broken down by A&E unit. • The health board's policy for when a patient arrives in Accident and Emergency with dental sepsis.
Date of Response: 27/03/2025
View Response: 9803.pdf
Freedom of Information Request Reference: 9800
Date Received: 28/02/2025
Summary:
1. How many GP practices within NHS Lothian have signed up for the direct and locally enhanced services contract for 25/26. 2. What is the current salary of the Director of Primary Care for 24/25 and for 25/26.
Date of Response: 28/03/2025
View Response: 9800.pdf
Freedom of Information Request Reference: 9741
Date Received: 11/02/2025
Summary:
• All internal or external guidance, policies, procedures or protocols in place regarding the provision of end-of-life care for children by NHS Lothian, including but not limited to those related to pain management and symptom control. • Any internal or internal correspondence held by NHS Lothian relating to such guidance, policies, procedures or protocols. • Details held in relation to any training provided to healthcare professionals employed by, or operating on behalf of, NHS Lothian which covers the delivery of end-of-life care to children and their families. • Any information held which demonstrates the number of children who received palliative sedation as part of their end-of-life care in the past two years. • All internal or external guidance, policies, procedures, protocols, and correspondence relating to the use of palliative sedation in children, including the types of sedatives used and the monitoring procedures followed. • All internal or external guidance, policies, procedures, protocols and correspondence regarding the provision of end-of-life care for neurodivergent children specifically, including specific considerations for their communication needs, sensory sensitivities, and potential co-occurring mental health conditions. • How are the specific needs of neurodivergent children are assessed and incorporated into their end-of-life care plans? Such needs include communication preferences, sensory sensitivities, and management of any co-occurring mental health conditions. • What provisions are in place to support families of neurodivergent children during the end-of-life care process, including access to specialist support services?
Date of Response: 04/04/2025
View Response: 9741.pdf
Freedom of Information Request Reference: 9712
Date Received: 05/02/2025
Summary:
1. What are the current wait times (as of today’s date) for Assessment of the following: a. Adult ADHD b. Adult Neurodiverse c. Child ADHD d. Child Neurodiverse 2. I see from FOI 9456 that it should be noted that the majority of adults are not on a specific ADHD waitlist. Could you explain: a. Why there is a separate waitlist for some adults & what is the distinction between them b. If adults on the specific ADHD waitlist wait less time than adults on the ND list 3. How many full time staff/ FTE - for the periods 24/25 and 23/24 and 22/23 - are able to diagnose: a. Adult ADHD b. Adult Neurodiverse c. Child ADHD d. Child Neurodiverse 4. If diagnosed with ADHD, how long till titration begins for: a. Adults b. Children
Date of Response: 04/04/2025
View Response: 9712.pdf
Freedom of Information Request Reference: 9799
Date Received: 27/02/2025
Summary:
Information requested: How many a) Type 1 diabetic adults and b) Type 1 diabetic children are currently waiting for Hybrid Closed Loop Technology and how many i) Type 1 diabetic adults and ii) Type 1 diabetic children were onboarded to Hybrid Closed Loop Technology in the year 2024-2025.
Date of Response: 02/04/2025
View Response: 9799.pdf
Freedom of Information Request Reference: 9798
Date Received: 27/02/2025
Summary:
Please provide me with all guidance the Health Board has regarding transgender staff. Please provide me with all guidance the Health Board has regarding female staff.
Date of Response: 25/03/2025
View Response: 9798.pdf
Freedom of Information Request Reference: 9797
Date Received: 27/02/2025
Summary:
Please tell me how many complaints the board has had relating to: • The use of female changing rooms/loos by transwomen • The use of male changing rooms/loos by transmen In each year from 2020 to the current year, 2025.
Date of Response: 27/03/2025
View Response: 9797.pdf
Freedom of Information Request Reference: 9795
Date Received: 27/02/2025
Summary:
In regards to question 2 if the request is amended to only specialities that are involved in performing robotic procedures would that change the outcome of the FOI? Secondly, would it please be possible to request the introduction years for each robotic system?
Date of Response: 24/03/2025
View Response: 9795.pdf
Freedom of Information Request Reference: 9794
Date Received: 26/02/2025
Summary:
1. Has this health board made any estimate of how much it expects to pay in employer National Insurance Contributions in 2025-26? Please provide as much detail as possible. 2. In 2024-25, how much did this health board pay in employer National Insurance Contributions? 3. In 2023-24, how much did this health board pay in employer National Insurance Contributions?
Date of Response: 25/03/2025
View Response: 9794.pdf
Freedom of Information Request Reference: 9793
Date Received: 26/02/2025
Summary:
1. Does the Authority currently have a Total Bed Management contract in place? If so, could you tell e when this expires? 2. Could the Authority outline what assets are under the Total Bed Management contract. 3. Will the Authority look to put the contract out to tender after the expiry date? 4. If this will be tendered, will the Authority split the tender requirements into different lots to make the process easier, i.e. Lot 1: beds, Lot 2: mattresses.
Date of Response: 26/03/2025
View Response: 9793.pdf
Freedom of Information Request Reference: 9792
Date Received: 26/02/2025
Summary:
I would like the following questions answered, to look at the products used and to establish if they are any BIOCIDES / NON -LICENSED products being used to prepare patients skin prior to surgical/invasive procedures. The date range requested would be JAN 2024 - JAN 2025. 1. Would it be possible to provide me with a list of current Chlorhexidine in Alcohol products used specifically within Main Theatres and Day Surgery across the Health Board as a preoperative skin disinfection prior to invasive / surgical procedure. 2. Which percentage of Chlorhexidine in Alcohol is most frequently used throughout the Health Board in the Anaesthetic Rooms a 0.5% CHG or 2% CHG. 3. Are the Chlorhexidine in Alcohol products the Health Board currently use prior to invasive / surgical procedures classified as Licensed Medicinal Products or Biocides. 4. If using a BIOCIDE which is not licensed as a preoperative skin disinfectant on a patient prior to an invasive / surgical procedure are patients notified and do you seek consent from each patient to use a non-licensed product 5. If you are using a BIOCIDE, are your staff trained in the use of a BIOCIDES
Date of Response: 26/03/2025
View Response: 9792.pdf
Freedom of Information Request Reference: 9791
Date Received: 26/02/2025
Summary:
Could you kindly answer the following questions: 1. I wish to know how much your trust has spent on specialist bariatric equipment for obese/bariatric patients (patients over 160kg) during the last three financial years? 2. Please give a breakdown of the type of equipment used by the trust and the amounts spent, split between Rental expenditure and Purchased Equipment? 2.1. If equipment used is on a Rental basis, please specify if this was under a contract basis or ad hoc? 2.2. When is the contract due for renewal? 2.3. If known, who is the contract with? 2.4. If under a contract, please supply the means of contract award, i.e framework or direct award.
Date of Response: 25/03/2025
View Response: 9791.pdf
Freedom of Information Request Reference: 9789
Date Received: 24/02/2025
Summary:
In the entrance, there’s a welcome sign in a wide range of languages, which is lovely. But, this is Scotland and you’ve failed to include Scots Gaelic. Why? Do you think that would happen in any other country, like Wales, Norway, Switzerland? The sign to be replaced to include Gaelic. I would also like to see a copy of the trust’s Gaelic language plan.
Date of Response: 24/03/2025
View Response: 9789.pdf
Freedom of Information Request Reference: 9788
Date Received: 26/02/2025
Summary:
• In terms of the Board’s obligations under the Equality Act 2010 to protect individuals from discrimination and harassment on the basis of protected characteristics, including sex, religion or belief and gender reassignment, I ask the Board to provide me with a copy of the Board’s current policy on the provision of changing facilities for staff • details on what steps have been taken by the Board to ensure that the rights of different groups are balanced in the application of these policies • details on how the Board has implemented obligations, and brought these to the attention of all staff, under the Workplace (Health, Safety and Welfare) Regulations 1992 which state that changing facilities will not be suitable “unless they include separate facilities for, or separate use of facilities by, men and women where necessary for reasons of propriety” • a copy of the Board’s Equality and Diversity Impact Assessment on the policy covering the provision of changing facilities for staff and including the obligations under the Workplace (Health, Safety and Welfare) Regulations 1992
Date of Response: 21/03/2025
View Response: 9788.pdf
Freedom of Information Request Reference: 9745
Date Received: 12/02/2025
Summary:
1. How many people were waiting to access pulmonary rehabilitation each month from January 2022 to December 2024? 2. What the average waiting time per patient accessing pulmonary rehabilitation is? 3. What is the longest waiting time for a patient accessing pulmonary rehabilitation for each quarter since January 2022? 4. How many vacancies there are for staff working in pulmonary rehabilitation, broken down by grade and band?
Date of Response: 02/04/2025
View Response: 9745.pdf
Freedom of Information Request Reference: 9730
Date Received: 10/02/2025
Summary:
1. For each A&E in the health board, please provide the total bed capacity. 2. For each of these A&E, please outline whether the service operated within or beyond capacity and by how much, broken down by month from January 2024 to January 2025.
Date of Response: 02/04/2025
View Response: 9730.pdf
Freedom of Information Request Reference: 9721
Date Received: 07/02/2025
Summary:
1. How many people were on a waiting list for an audiology appointment at the end of January 2025 (if possible please give the number as it stood at January 31 or closest to that date from figures available)? 2. What does the board estimate to be the average waiting times for each of the following audiology appointment groups: a) audiology assessment (first contact) appointment, b) assessment to fitting of hearing aid(s), c) assessment to treatment (excluding fitting of hearing aids). 3. The national target in Scotland is 18 weeks for Referral to Treatment. Using your latest recorded figures please state the percentage (%) of patients that were seen within the national target waiting time and the time period to which this figure refers.
Date of Response: 02/04/2025
View Response: 9721.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS